Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications

Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21.

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2(+) breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / metabolism*
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • ERBB2 protein, human
  • Receptor, ErbB-2